Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GCK | P35557 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176452 | 1.00 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2176805 | 0.91 | GCK (0.52) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2176801 | 0.91 | GCK (0.52) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2178114 | 0.87 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2178106 | 0.87 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2180468 | 0.85 | GCK (0.52) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2180467 | 0.85 | GCK (0.52) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2175619 | 0.85 | GCK (0.53) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2175613 | 0.85 | GCK (0.53) | NPC1RAB9ASMN1; SMN2HPGDGCK | |
| SCHEMBL2177361 | 0.84 | GCK (0.53) | NPC1RAB9ASMN1; SMN2HPGDGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | claimed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | claimed |
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | NPC1 3351/4885RAB9A 3743/4885SMN1; SMN2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.